Diagnocure Inc (DGCRF) 0.1080 $DGCRF
DiagnoCure announces second quarter 2015 results and restructures its Board of directors
PR Newswire - Fri Jun 12, 6:30AM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"

today reported financial and operational results for the second quarter ended April 30, 2015. The Corporation announced a net loss of $567,991 or $0.01 per share for this quarter. At the end of the quarter, cash and temporary investments stood at $1,574,957. Operating expenses, before restructuring charges of $188,964, decreased by $158,278, to $508,812 for the second quarter of 2015 from $667,090 for the same period of 2014. The net loss before non-cash elements and restructuring charges decreased by a third, from $431,706 for the second quarter of 2014 to $289,228 for the same period of 2015. These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015.
CUR.TO: 0.11 (unch)
DiagnoCure's new prostate cancer multimarker urine test featured at a recent press event of the American Urological Association
CNW Group - Wed May 20, 4:01PM CDT
DiagnoCure Inc. (TSX: CUR; OTCQX: DGCRF) (the "Corporation"

today reports that the results of the prospective trial on its prostate cancer panel (PCP) urine test were well received by the urologist community attending the 2015 Annual Meeting of the American Urological Association (AUA) held from May 15 to May 19 in New Orleans, Louisiana.
CUR.TO: 0.11 (unch)
DiagnoCure announces results of its Annual and General Meeting of shareholders
PR Newswire - Thu Apr 30, 5:30PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"

today announced that its shareholders have approved all resolutions presented to them in the Management Proxy Circular dated March 5, 2015 and put forth for vote during the shareholders meeting held today in Montreal.
CUR.TO: 0.11 (unch)
DiagnoCure provides business up-date
CNW Group - Thu Apr 23, 4:00PM CDT
DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"

today reports on its continuing efforts to improve corporate value for its shareholders and preserving operating funds to ensure all options for the Corporation. These continuing efforts include: (1) maintaining productive discussions regarding the licensing of the Corporation's assets, (2) continuing discussions with a select group of companies regarding a potential strategic combination of assets and, (3) implementation of additional steps under the contingency plan of the Corporation.
CUR.TO: 0.11 (unch)
DiagnoCure announces fourth quarter 2014 and year-end results
CNW Group - Fri Jan 23, 6:30AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"

today reported financial and operational results for the fourth quarter 2014 and fiscal year ended October 31, 2014. The Corporation announced a net loss of $461,710 or $0.01 per share for the fourth quarter ended October 31, 2014, compared to $1,334,099 or $0.03 per share for the same period in 2013 and a net loss of $2,032,151 or $0.05 per share for fiscal year 2014 compared to $3,566,942 or $0.08 per share for the same period in 2013. At the end of the quarter, cash and short-term investments stood at $2,227,326 compared to $4,190,296 at the end of fiscal year 2013.
CUR.TO: 0.11 (unch)
Diagnocure Reports on Corporate Initiatives for 2014
PR Newswire - Thu Oct 30, 4:01PM CDT
Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved
CUR.TO: 0.11 (unch)
DiagnoCure announces results for third quarter of 2014
PR Newswire - Thu Sep 11, 4:01PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"

today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to a decrease in PCA3 royalties paid to DiagnoCure. Operating expenses decreased by $127,318 or 16%, to $657,529 for the third quarter of 2014 from $784,847 for the same period of 2013. At the end of the quarter, cash and short-term investments stood at $2,541,852.
CUR.TO: 0.11 (unch)